Why Atai Life Sciences Stock Was So Lively This Week
Key Points
The biotech earned an important fast-track review designation from a major regulator.
This should speed the development (and potentially, commercialization) of one of its investigational treatments.
Atai Life Sciences (NASDAQ: ATAI), a biotech focused on developing psychedelic-based medicines to treat mental health disorders, was a standout stock over the past few days in its rather limited peer group.
That's because news of a top regulator's move on one of its developmental drugs was pushing the company's stock up by nearly 8% week to date as of early Friday morning, according to data compiled by S&P Global Market Intelligence.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks »
Reporting a breakthrough
On Thursday, Atai announced that it and its clinical partner Beckley Psytech had received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for their investigational treatment BPL-003. This is a nasal spray that targets treatment-resistant depression (TRD) in adult patients.
Image source: Getty Images.
The Breakthrough Therapy designation is granted to drugs being developed to treat serious or life-threatening conditions. They must show significant progress over other treatments in the development stage to be considered for the tag, which fast-tracks the FDA's review and approval process.
BPL-003 is entering the final stages of its clinical life; Atai said it expects to launch phase 3 testing of the drug in the second quarter of 2026.
Time for some capital raising
Atai is wasting almost no time gearing up for that stage. Also on Thursday, the company priced a secondary issue of its common stock. Just over 23.7 million shares are to be sold in a public offering, at a price of $5.48 apiece. The underwriters of the flotation have been granted a 30-day option to collectively purchase up to nearly 3.6 million shares at the same price.
The gross proceeds of the issue should amount to roughly $130 million. Atai will use the capital raise to, sensibly enough, advance its clinical programs. It will also channel some of the funds to "working capital and general corporate purposes."
The issue is expected to close next Monday, Oct. 20.
Should you invest $1,000 in Atai Life Sciences right now?
Before you buy stock in Atai Life Sciences, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Atai Life Sciences wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $648,924!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,102,333!*
Now, it’s worth noting Stock Advisor’s total average return is 1,052% — a market-crushing outperformance compared to 190% for the S&P 500. Don’t miss out on the latest top 10 list, available when you join Stock Advisor.
*Stock Advisor returns as of October 13, 2025
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Related Articles
Investing in Digital Payments & Blockchain
TradingKey - The global payments system is undergoing one of the most profound restructuring episodes in its history. Cash is being rapidly replaced by digital substitutes, ranging from contactless cards and wallets on mobile devices to blockchain-based networks.
Trump to Interview Fed Chair Candidates: A Dove is Most Likely to Be Selected, Bullish for Gold
TradingKey - In recent years, gold has experienced an epic bull market, with prices soaring continuously, allowing gold bulls to reap substantial profits (Figure 1). Looking ahead, can gold bulls—particularly medium- to long-term investors employing a buy-and-hold strategy—continue to achieve high..
JPMorgan’s $1Trillion Bet on Security & Resilience: National Security Stocks as New Safe Havens
TradingKey - On Monday, JPMorgan announced a sweeping 10-year strategic investment plan under the theme of “Security & Resilience”—an initiative that could involve up to $1 trillion in capital deployment across four high-priority sectors.
Trump Meets Zelenskyy: Selling Tomahawk Missiles, Gold Investors Set to Profit Big?
Should this plan materialise, it could escalate the Russia-Ukraine conflict, heightening global uncertainty and further driving gold prices upward.-490cffb0533749cf929fbf39e5a7ed2d.jpg)
TSMC Q3 Earnings Preview: Record Revenue Is a Lock, but an Upgraded Outlook Could Be the Real Catalyst
TradingKey - Global semiconductor foundry leader Taiwan Semiconductor Manufacturing Company (TSMC, TSM) will report its Q3 2025 earnings on Thursday, October 16, before U.S. markets open. With record-breaking revenue already confirmed by monthly reports, analysts expect record profits and-f8d64d3844fb416dac43dbc6861db8ff.jpg)
